BioSpace News Archive

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company’s President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.

MedMira Inc. announces the receipt of a Canadian patent patent for its new innovative and quantitative test system.

Global architecture firm Corgan has been awarded a $30,000 research grant from the American Society of Interior Designers (ASID) Foundation to study the experiences of teachers with disabilities — a diverse community with limited representation in existing research.

Zomedica Corp. announced that it is continuing dialogue with senior regulatory staff at the NYSE American regarding next steps to regaining compliance with its listing standards.

Travere Therapeutics, Inc. announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,600 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,600 shares of its common stock.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.

Intellipharmaceutics International Inc. announces its listing on NEX, a separate board of the TSX Venture Exchange.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023.